Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (29)

I-002Seef Abdalla

Pharmacokinetics of Cefotaxime and its metabolite Desacetyl-cefotaxime to optimize dosing in critically ill children and children with Sickle Cell Disease.

Wednesday 10:30-12:00

I-036Lisanne Bevers

A pooled population PK analysis investigating once-daily standard dosing of DTG in HIV/TB co-infected children weighing 3 kg or more.

Wednesday 10:30-12:00

I-045Andrew Brandon

Population pharmacokinetics of mitoxantrone in children with cancer

Wednesday 10:30-12:00

I-061Amy S. Y. Cheung

Cabotegravir Population Pharmacokinetic Analysis of Adult and Adolescents pooled population who are living with HIV or at risk for HIV and receiving HIV pre-exposure prophylaxis (PrEP)

Wednesday 10:30-12:00

I-086AHM de Vries Schultink

Population pharmacokinetics of total and protein-unbound prednisolone in children with immune-mediated and inflammatory diseases

Wednesday 10:30-12:00

I-100Nassim DJEBLI

Population Pharmacokinetic modeling of Dexmedetomidine Nasal Spray in Chinese adults and children

Wednesday 10:30-12:00

I-103Stephen Duffull

Investigating survivorship bias in disease progression modelling for Duchenne muscular dystrophy

Wednesday 10:30-12:00

II-010Pablo Gamallo

Population PK/PD modelling and simulation for nedosiran dose guidance in children with primary hyperoxaluria type 1

Wednesday 15:30-17:00

II-014Gastón García-Orueta

Optimal study design for pharmacokinetic modeling of teicoplanin, piperacillin and meropenem in critically ill children, including those undergoing Continuous Kidney Replacement Therapy

Wednesday 15:30-17:00

II-056Seongmee Jeong

Model-based dosage optimization of sirolimus for vascular anomalies on pediatrics

Wednesday 15:30-17:00

II-075Anisa Khan

Exploring the implications of poor acceptability on treatment adherence and response in children: an in-silico simulation study of deferasirox and amoxicillin

Wednesday 15:30-17:00

II-089Elke Krekels

Changes in the relative contribution of hepatic metabolism and glomerular filtration to total plasma clearance in children younger than four years of age; when is scaling for the dominant elimination route in adults appropriate?

Wednesday 15:30-17:00

II-098Anna Largajolli

Validating the D-RSC disease progression modelling framework for Duchenne muscular dystrophy and evaluating the long-term impact of givinostat therapy in pediatric patients

Wednesday 15:30-17:00

II-109Karen Leys

Physiologically-based prediction of pharmacokinetics in neonates suffering perinatal asphyxia and undergoing therapeutic hypothermia – midazolam and its metabolites as case example

Wednesday 15:30-17:00

III-007Ioannis Loisios Konstantinidis

Dose confirmation of asciminib in pediatric patients after oral administration in fasted and low fat fed states using physiologically based pharmacokinetic modeling and simulations

Thursday 9:50-11:45

III-018Ruvarashe Joylyne Madzime

Population pharmacokinetics of high-dose isoniazid in children receiving the 3-month weekly rifapentine and isoniazid (3HP) regimen for TB preventive treatment

Thursday 9:50-11:45

III-020Junjun Mao

A Semi-Mechanistic Model with Glutathione S-transferase Activity to Optimize Busulfan Dosing in Pediatric Hematopoietic Stem Cell Transplantation

Thursday 9:50-11:45

III-065Michal Pac

Characterising target organ damage in paediatric patients with primary hypertension: a time-to-event analysis

Thursday 9:50-11:45

III-066Faheemah Padavia

Paracetamol concentrations and time-course of ductus arteriosus diameter in extreme preterm neonates: a population pharmacokinetic-pharmacodynamic analysis

Thursday 9:50-11:45

III-072Orestis Papatryfonos

Development of a Population PK-PD Model for Tapentadol to Assess Postoperative Pain in Children Aged 6 to <12 using Nonlinear Mixed-Effects Modelling

Thursday 9:50-11:45

III-082Soumya Perinparajah

Towards Developing a Harmonizing Framework for PK and/or PKPD Scaling for Pain Medications in the Pediatric Population

Thursday 9:50-11:45

III-094Laure-Hélène Préta

Prediction of maternal and fetal exposure to escitalopram, sertraline and paroxetine by combining human ex vivo placenta perfusion data and physiologically-based pharmacokinetic modeling

Thursday 9:50-11:45

IV-007Mohammed Rohi Sanoufi

Population pharmacokinetics of intravenous linezolid in critically ill paediatric patients

Thursday 15:00-16:45

IV-032Jugal Suthar

Improving Predictive Accuracy in Vincristine PopPK Models Through Model Averaging and Dataset Augmentation

Thursday 15:00-16:45

IV-050Lufina Tsirizani

Population pharmacokinetics of first-line TB drugs in Haitian children under 5 years old, and accuracy of finger stick capillary sampling technique.

Thursday 15:00-16:45

IV-063Jennie van Dyk

Pharmacokinetics of ritonavir-boosted atazanavir in children and adolescents with HIV: Analysis of CHAPAS-4 and VirTUAL trials

Thursday 15:00-16:45

IV-083Xiaoning (Shelly) Wang

Population Pharmacokinetic Analysis of Emtricitabine in Adolescents and Children with HIV-1

Thursday 15:00-16:45

IV-095Maria Xiberras

Repeated time to event modelling of morphine pharmacodynamics for analgesia after paediatric cardiac surgery

Thursday 15:00-16:45

IV-114Yuanxi Zou

QT interval prolongation in children receiving moxifloxacin and clofazimine for rifampicin-resistant tuberculosis treatment in South Africa, India, and the Philippines

Thursday 15:00-16:45